HDAC9 and meningioma: Using this model, we demonstrated the therapeutic potential of the combination therapy of the MERTK inhibitor UNC2025 and the HDAC inhibitor Trichostatin A (TSA) to treat patient derived WHO grade 1 and grade 2 meningiomas.